Dr. Alan Roth — AI in Drug Discovery, AI Innovation and Limitations, Human Oversight

Dr. Alan Roth, CEO of Oxford Drug Design, has a diverse background in life sciences spanning research, capital markets, consultancy, and company leadership. He began as a chemist at Merck in New Lead Discovery, later serving as a consultant at McKinsey and Director at Commerzbank Asset Management overseeing bio-investments. He co-founded and led Chiral Quest, Inc., and was a Royal Society Entrepreneur in Residence at Oxford, where he is also a Visiting Lecturer. He holds degrees from Cornell, Columbia, and Oxford. Dr. Alan Roth LinkedIn: https://www.linkedin.com/in/alandroth/?originalSubdomain=uk Website: http://www.oxforddrugdesign.com/ Flor Laorga LinkedIn: https://www.linkedin.com/in/flor-laorga/ X: https://x.com/florlaorga Website: https://aifn.co/flor AI Frontier Network Website: https://aifn.co LinkedIn: https://www.linkedin.com/company/ai-frontier-network/ X: https://x.com/aifn_co YouTube: https://www.youtube.com/@ai-frontier-network OUTLINE 00:00 Start 00:25 Meet Dr. Alan Roth, Life Sciences Entrepreneur 00:56 From Academic Chemist to Industry Leader 04:53 How AI Advances Drug Discovery Processes 13:00 Overcoming Hurdles in Biotech Innovation 24:14 Balancing AI and Human Insight in R&D 30:46 Lessons for Future Scientists and Entrepreneurs 32:43 Staying Human in a High-Tech Future